# US 2010/0172864 A1 · Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0172864 A1
- Document ID: US20100172864A1
- Status: Published application
- Kind: A1
- Application number: 12/714,147
- Filed: 2010-02-26
- Published: 2010-07-08
- Earliest claimed: 2001-09-07
- Assignees: Board of Regents, The University of Texas System
- Inventors: Wadih Arap; Mikhail G. Kolonin; Paul J. Mintz; Renata Pasqualini; Amado J. Zurita
- Web page: https://patentgrep.com/patent/US20100172864A1

## CPC

- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/642: {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
- C07K 5/0819: {with the first amino acid being acidic}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/77: Internalization into the cell
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/00043: viral genome or elements thereof as genetic vector
- C12N 2795/00045: Special targeting system for viral vectors
- C12N 2795/00062: by genetic engineering
- C12N 2795/00071: Demonstrated in vivo effect
- C12N 2810/40: Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N 2830/60: from viruses
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern a novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

## Claims

### Claim at position 1

-57. (canceled)

### Claim 58

A peptide of 50 amino acids or less in size, comprising an IL-11Rα targeting motif having the amino acid sequence of any of SEQ ID NO:5 through SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:35, or SEQ TD NO:37.

### Claim 59 (depends on 58)

The peptide of claim 58, wherein said peptide is 25 amino acids or less in size.

### Claim 60 (depends on 59)

The peptide of claim 59, wherein said peptide is 10 amino acids or less in size.

### Claim 61 (depends on 60)

The peptide of claim 60, wherein said peptide is 7 amino acids or less in size.

### Claim 62 (depends on 58)

The method of claim 58, wherein the peptide comprises an amino acid sequence selected from SEQ ID NO:34 or SEQ ID NO:37.

### Claim 63 (depends on 58)

The peptide of claim 58, wherein the peptide is conjugated or fused to a second agent.

### Claim 64 (depends on 63)

The peptide of claim 63, wherein the second agent is a polypeptide.

### Claim 65 (depends on 63)

The peptide of claim 63, wherein the second agent is a therapeutic or diagnostic agent.

### Claim 66 (depends on 65)

The peptide of claim 65, wherein the therapeutic agent is a drug, a chemotherapeutic agent, a radioisotope, a pro-apoptosis agent, an anti-angiogenic agent, a survival factor, an anti-apoptotic agent, an enzyme, a hormone, a hormone antagonist, a cytokine, a cytotoxic agent, a cytocidal agent, a cytostatic agent, a growth factor, a peptide, a protein, an antibiotic, an antibody, a Fab fragment of an antibody, a hormone antagonist, a nucleic acid, an antigen, a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a microdevice, a yeast cell, a mammalian cell, a cell or an expression vector.

### Claim 67 (depends on 66)

The peptide of claim 66, wherein the second agent is an anti-angiogenic agent selected from the group consisting of thrombospondin, angiostatin, pigment epithelium-derived factor, angiotensin, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, platelet factor 4, IP-10, Gro-β, thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin 2 (Regeneron), interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, Docetaxel, polyamines, a proteasome inhibitor, a kinase inhibitor, a signaling peptide, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4, and minocycline.

### Claim 68 (depends on 66)

The peptide of claim 66, wherein the second agent is a pro-apoptosis agent selected from the group consisting of gramicidin, magainin, mellitin, defensin, cecropin, (KLAKLAK)2 (SEQ ID NO:1), (KLAKKLA)2 (SEQ ID NO:2), (KAAKKAA)2 (SEQ ID NO:3) and (KLGKKLG)3 (SEQ ID NO:4).

### Claim 69 (depends on 69)

The peptide of claim 69, wherein the pro-apoptosis agent is (KLAKLAK)2 (SEQ ID NO:1).

### Claim 70 (depends on 66)

The peptide of claim 66, wherein the second agent is a cytokine selected from the group consisting of interleukin 1 (IL-1), IL-2, IL-5, IL-10, IL-12, IL-18, interferon-γ (IF-γ), IF α, IF-β, tumor necrosis factor-α (TNF-α), or GM-CSF (granulocyte macrophage colony stimulating factor).

### Claim 71 (depends on 63)

The peptide of claim 63, wherein the second agent is a molecular complex.

### Claim 72 (depends on 71)

The peptide of claim 71, wherein the complex is a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a yeast cell, a mammalian cell or a cell.

### Claim 73 (depends on 72)

The peptide of claim 72, wherein the complex is a virus or a bacteriophage.

### Claim 74 (depends on 73)

The peptide of claim 73, wherein the virus is chosen from the group consisting of adenovirus, retrovirus adeno-associated virus (AAV), and AAVP.

### Claim 75 (depends on 65)

The peptide of claim 65, wherein the second agent is a diagnostic agent.

### Claim 76 (depends on 75)

The peptide of claim 75, wherein the diagnostic agent is an imaging agent.

### Claim 77 (depends on 76)

The peptide of claim 76, wherein the imaging agent, wherein the imaging agent comprises chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) erbium (III), lanthanum (III), gold (III), lead (II), or bismuth (III).

### Claim 78 (depends on 75)

The method of claim 75, wherein the agent comprises a radioisotope, and the radioisotope is astatine211, 14carbon, 51chromium, 36chlorine, 57cobalt, 58cobalt, copper67, 152Eu, gallium67, 3hydrogen, iodine123, iodine125, iodine131, indium111, 59iron, 32phosphorus, rhenium186, rhenium188, 75selenium, 35sulphur, technicium99m or yttrium90.

### Claim 79 (depends on 1)

The peptide of claim 1, further defined as comprising SEQ ID NO:5 and SEQ ID NO: 1.

### Claim 80 (depends on 58, 79)

A pharmaceutical composition comprising the peptide of claim 58 or 79, in a pharmaceutically acceptable medium.
